{"Symbol": "ACAD", "AssetType": "Common Stock", "Name": "ACADIA Pharmaceuticals Inc", "Description": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.", "CIK": "1070494", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "12830 EL CAMINO REAL, SAN DIEGO, CA, UNITED STATES, 92130", "OfficialSite": "https://www.acadia.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "3727076000", "EBITDA": "108458000", "PERatio": "14.21", "PEGRatio": "-0.42", "BookValue": "5.42", "DividendPerShare": "None", "DividendYield": "None", "EPS": "1.55", "RevenuePerShareTTM": "6.25", "ProfitMargin": "0.249", "OperatingMarginTTM": "0.128", "ReturnOnAssetsTTM": "0.0511", "ReturnOnEquityTTM": "0.349", "RevenueTTM": "1047118000", "GrossProfitTTM": "617766000", "DilutedEPSTTM": "1.55", "QuarterlyEarningsGrowthYOY": "1.128", "QuarterlyRevenueGrowthYOY": "0.113", "AnalystTargetPrice": "31.21", "AnalystRatingStrongBuy": "4", "AnalystRatingBuy": "9", "AnalystRatingHold": "6", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "14.21", "ForwardPE": "34.01", "PriceToSalesRatioTTM": "3.559", "PriceToBookRatio": "4.063", "EVToRevenue": "2.803", "EVToEBITDA": "27.06", "Beta": "0.66", "52WeekHigh": "28.35", "52WeekLow": "13.4", "50DayMovingAverage": "26.1", "200DayMovingAverage": "23.31", "SharesOutstanding": "169182000", "SharesFloat": "125340000", "PercentInsiders": "0.543", "PercentInstitutions": "99.351", "DividendDate": "None", "ExDividendDate": "None"}